Polypharmacological Drugs: "Magic Shotguns" for Psychiatric Diseases

Polypharmacology in Drug Discovery

Volumn , Issue , 2012, Pages 133-148

  Kroeze, Wesley K ^a   Roth, Bryan L ^a,b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

"receptoromic," predicting drug promiscuity; Polypharmacological drugs: "Magic Shotguns"; Psychiatric drug promiscuity, "functionally selective"

Indexed keywords

EID: 84879257335     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118098141.ch7     Document Type: Chapter

References (46)

1. Wong, E. H. F., Tarazi, F. I., Shahid, M. (2010), The effectiveness of multi-target agents in schizophrenia and mood disorders: Relevance of receptor signature to clinical action, Pharmacol. Ther. 126, 173-185.
2. Roth, B. L.; Sheffler, D. J.; Kroeze, W. K. (2004), Magic shotguns versus magic bullets: Selectively non-selective drugs for mood disorders and schizophrenia, Nature Rev. Drug Discov. 3, 353-359.
3. Bianchi, M. T.; Pathmanathan, J.; Cash, S. S. (2009), From ion channels to complex networks: Magic bullet versus magic shotgun approaches to anticonvulsant pharmacotherapy, Med. Hypoth. 72, 297-305.
4. Jensen, N. H.; Roth, B. L. (2008), Massively parallel screening of the receptorome, Combin Chem. High Throughput Screen. 11, 420-426.
5. Paolini, G. V.; Shapland, R. H. B.; van Hoorn,W. P.; Mason, J. S.; Hopkins, A. L. (2006), Global mapping of pharmacological space, Nature Biotechnol. 24, 805-815.
6. Armbruster, B. N.; Roth, B. L. (2005), Mining the receptorome, J. Biol. Chem. 280, 5129-5132.
7. Roth, B. L. (2005), Receptor systems:Will mining the receptorome yield novel targets for pharmacotherapy? Pharmacol. Ther. 108, 59-64.
8. Roth, B. L.; Kroeze, W. K. (2006), Screening the receptorome yields validated molecular targets for drug discovery, Curr. Pharm. Design 12, 1785-1795.
9. Strachan, R. T.; Ferrara, G.; Roth, B. L. (2006), Screening the receptorome: An efficient approach for drug discovery and target validation, Drug Discov. Today 11, 708-716.
10. Setola, V.; Dukat, M.; Glennon, R. A.; Roth, B. L. (2005), Molecular determinants for the interaction of the valvulopathic anorexigen norfenfluramine with the 5-HT2B receptor, Mol. Pharmacol. 68, 20-33.
11. Kroeze,W. K.; Hufeisen, S. J.; Popadak, B. A.; Renock, S. M.; Steinberg, S.; Ernsberger, P.; Jayathilake, K.; Meltzer, H. Y.; Roth, B. L. (2003), H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs, Neuropsychopharmacology 28, 519-526.
12. Roth, B. L.; Baner, K.;Westkaemper, R.; Siebert, D.; Rice, K. C.; Steinberg, S.; Ernsberger, P.; Rothman, R. B. (2002), Salvinorin A: A potent naturally occurring nonnitrogenous kappa opioid selective agonist, Proc. Natl. Acad. Sci USA 99, 11934-11939.
13. Keiser, M. J.; Roth, B. L.; Armbruster, B. N.; Ernsberger, P.; Irwin, J. J.; Shoichet, B. K. (2007), Relating protein pharmacology by ligand chemistry. Nature Biotechnology 25, 197-206.
14. Keiser,M. J.; Setola,V.; Irwin, J. J.; Laggner, C.; Abbas, A. I.; Hufeisen, S. J.; Jensen, N. H.; Kuijer,M. B.; Matos, R. C.; Tran, T. B.; Whaley, R.; Glennon, R. A.; Hert, J.; Thomas, K. L. H.; Edwards, D. D.; Shoichet, B. K.; Roth, B. L. (2009), Predicting new molecular targets for known drugs, Nature 462, 175-181.
15. Hopkins, A. L. (2009), Drug Discovery: Predicting promiscuity, Nature 462, 167-168.
16. Hergenrother, P. J. (2006), Obtaining and screening compound collections: A user's guide and a call to chemists, Curr. Opin. Chem. Biol. 10, 213-218.
17. Mestres, J.; Gregori-Puigjane, E.;Valverde, S.; Sole, R.V. (2008), Data completeness-the Achilles heel of drug-target networks, Nature Biotechnol. 26, 983-984.
18. Gray, J. A.; Roth, B. L. (2007), The pipeline and future of drug development in schizophrenia, Mol. Psychiatry 12, 904-922.
19. Gregori-Puigjane, E.; Mestres, J. (2008), A ligand-based approach to mining the chemogenomic space of drugs, Combin. Chem. High Throughput Screen. 11, 669-676.
20. Hopkins, A. L.; Mason, J. S.; Overington, J. P. (2006), Can we rationally design promiscuous drugs? Curr. Opin. in Struct. Biol. 16, 127-136.
21. Enna, S. J.;Williams, M. (2009), Challenges in the search for drugs to treat central nervous system disorders, J. Pharmacol. Exp. Ther. 329, 404-411.
22. Porsolt, R. D.; Moser, P. C.; Castagne, V. (2010), Behavioral indices in antipsychotic drug discovery, J. Pharmacol. Exp. Ther. 333, 632-638.
23. Raju, T. N. (2000), The Nobel chronicles. 1988: James Whyte Black, (b 1924), Gertrude Elion (1918-99), and George H. Hitchings (1905-98), Lancet 355, 1022.
24. Brea, J.; Castro, M.; Loza, M. I.; Masaguer, C. F.; Ravina, E.; Dezi, C.; Pastor, M.; Sanz, F.; Cabrero-Castel, A.; Galan-Rodriguez, B.; Fernandez-Espejo, E.; Maldonado, R.; Robledo, P. (2006), QF2004B, a potential antipsychotic butyrophenone derivative with similar pharmacological properties to clozapine, Neuropharmacology 51, 251-262.
25. Abbenante, G.; Reid, R. C.; Fairlie, D. P. (2008), "Clean" or "dirty"-just how selective do drugs need to be? Austral. J. Chem. 61, 654-660.
26. Mestres, J.; Gregori-Puigjane, E.; Valverde, S.; Sole, R. V. (2009), The topology of drugtarget interaction networks: Implicit dependence on drug properties and target families, Mol. Biosyst. 5, 1051-1057.
27. Vogt, I.; Mestres, J. (2010), Drug-target networks, Mol. Inform. 29, 10-14.
28. Boran, A. D.; Iyengar, R. (2010), Systems approaches to polypharmacology and drug discovery, Curr. Opin. Drug Discov. Dev. 13, 297-309.
29. Bianchi, M. T.; Botzolakis, E. J. (2008), Targeting ligand-gated ion channels in neurology and psychiatry: Is pharmacological promiscuity an obstacle or an opportunity? BMC Pharmacol. 10, 3.
30. Mencher, S. K.; Wang, L. G. (2005), Promiscuous drugs compared to selective drugs (promiscuity can be a virtue), BMC Pharmacol. 5, 3.
31. Urban, J. D.; Clarke, W. P.; von Zastrow, M.; Nichols, D. E.; Kobilka, B.; Weinstein, H.; Javitch, J. A.; Roth, B. L.; Christopoulos, A.; Sexton, P. M.; Miller, K. J.; Spedding, M.; Mailman, R. B. (2007), Functional selectivity and classical concepts of quantitative pharmacology, J. Pharmacol. Exp. Ther. 320, 1-13.
32. Mailman, R. B.; Murthy, V. (2010), Third generation antipsychotic drugs: Partial agonism or receptor functional selectivity? Curr. Pharm. Design 16, 488-501.
33. Urban, J. D.; Vargas, G. A.; von Zastrow, M.; Mailman, R. B. (2007), Aripiprazole has functionally selective actions at dopamine D2 receptor-mediated signaling pathways, Neuropsychopharmacology 32, 67-77.
34. Coward, P.; Chan, S. D.;Wada, H. G.; Humphries, G. M.; Conklin, B. R. (1999), Chimeric G proteins allow a high-throughput signaling assay of Gi-coupled receptors, Anal. Biochem. 270, 242-248.
35. Kostenis, E.; Waelbroeck, M.; Milligan, G. (2005), Techniques: promiscuous Galpha proteins in basic research and drug discovery, Trends Pharmacol. Sci. 26, 595-602.
36. Morphy, R.; Rankovic, Z. (2005), Designed multiple ligands. An emerging drug discovery paradigm, J. Med. Chem. 48, 6523-6543.
37. Liu, Z. L.; Zhang, J.; Zhang, A. (2009), Design of multivalent ligand targeting G-proteincoupled receptors, Curr. Pharm. Design 15, 682-718.
38. Kenakin, T. P. (2010), Ligand detection in the allosteric world, J Biomol. Screen. 15, 119-130.
39. May, L. T.; Leach, K.; Sexton, P. M.; Christopoulos, A. (2007), Allosteric modulation of G protein-coupled receptors. Annu. Rev. Pharmacol. Toxicol. 47, 1-51.
40. Lewis, J. A.; Lebois, E. P.; Lindsley, C. W. (2008), Allosteric modulation of kinases and GPCRs: Design principles and structural diversity, Curr. Opin. Chem. Biol. 12, 269-280.
41. Bianchi, M. T. (2010), Promiscuous modulation of ion channels by anti-psychotic and antidementia medications, Med. Hypoth. 74, 297-300.
42. Peters, J. U.; Schnider, P.; Mattei, P.; Kansy, M. (2009), Pharmacological promiscuity: Dependence on compound properties and target specificity in a set of recent Roche compounds, ChemMedChem 4, 680-686.
43. Arnt, J.; Bang-Andersen, B.; Dias, R.; Bogeso, K. P. (2008), Strategies for pharmacotherapy of schizophrenia, Drugs Future 33, 777-791.
44. Conn, P. J.; Roth, B. L. (2008), Opportunities and challenges of psychiatric drug discovery: Roles for scientists in academic, industry, and government settings, Neuropsychopharmacology 33, 2048-2060.
45. Marino, M. J.; Knutsen, L. J.; Williams, M. (2008), Emerging opportunities for antipsychotic drug discovery in the postgenomic era, J. Med. Chem. 51, 1077-1107.
46. Mathew, S. J.; Manji, H. K.; Charney, D. S. (2008), Novel drugs and therapeutic targets for severe mood disorders, Neuropsychopharmacology 33, 2080-2092.